Improved production of adenovirus vectors expressing apoptotic transgenes

Human Gene Therapy

Volumn 11, Issue 1, 2000, Pages 139-149

  Bruder, Joseph T ^a   Appiah, Angela ^a   Kirkman, Wayne M ^a   Chen, Ping ^a   Tian, Jie ^a   Reddy, Damodar ^a   Brough, Douglas E ^a   Lizonova, Alena ^a   Kovesdi, Imre ^a  

^a GenVec   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; VIRUS VECTOR;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; TRANSGENE; VIRUS REPLICATION;

EID: 84941944734     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050016229     Document Type: Article

References (52)

1. Armstrong, R.C., Aja, T., Xiang, J., Gaur, S., Krebs, J.F., Hoang, K., Bai, X., Korsmeyer, S.J., Karanewsky, D.S., Fritz, L.C., and Tomaselli, K.J. (1996). Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J. Biol. Chem. 271, 16850-16855.
2. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Duke, R.C. (1995). A role for CD95 ligand in preventing graft rejection Nature (London) 377, 630-632.
3. Boldin, M.P., Varfolomeev, E.E., Pancer, Z., Mett, I.L., Camonis, J.H., and Wallach, D. (1995). A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270, 7795-7798.
4. Boldin, M.P., Goncharov, T.M., Goltsev, Y.V., and Wallach, D. (1996). Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 85, 803-815.
5. Chen, P., Tian, J., Kovesdi, I., and Bruder, J.T. (1998). Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J. Biol. Chem. 273, 5815-5820.
6. Chinnadurai, G., Chinnadurai, S., and Brusca, J. (1979). Physical mapping of a large-plaque mutation of adenovirus type 2. J. Virol. 32, 623-628.
7. Chinnaiyan, A.M., and Dixit, V.M. (1996). The cell-death machine. Curr. Biol. 6(5):555-562.
8. Chinnaiyan, A.M., O'Rourke, K., Tewari, M., and Dixit, V.M. (1995). FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81, 505-512.
9. Cirielli, C., Riccioni, T., Yang, C.L., PILI, R., Gloe, T., Chang, J., Inyaku, K., Passaniti, A., and Capogrossi, M.C. (1995). Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int. J. Cancer 63, 673-679.
10. Clarke, M.F., Abel, I.J., Benedict, M.A., Eipers, P.G., Sumantran, V., González-García, M., Doedens, M., Fukunaga, N., Davidson, B., Dick, J.E., Minn, A.J., Boise, L.H., Thompson, C.B., Wicha, M., and Núñez, G. (1995). A recombinant bcl-xS adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc. Natl. Acad. Sci. U.S.A. 92, 11024-11028.
11. Cleghon, V., Piderit, A., Brough, D.E., and Klessig, D.F. (1993). Phosphorylation of the adenovirus DNA-binding protein and epitope mapping of monoclonal antibodies against it. Virology 197, 564-575.
12. Ealovega, M.W., McGinnis, P.K., Sumantran, V.N., Clarke, M.F., and Wicha, M.S. (1996). bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res. 56, 1965-1969.
13. Enari, M., Hug, H., and Nagata S. (1995). Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature (London) 375, 78-81.
14. Fernandes-Alnemri, T., Armstrong, R.C., Krebs, J., Srinivasula, S.M., Wang, L., Bullrich, F., Fritz, L.C., Trapani, J.A., Tomaselli, K.J., Litwack, G., and Alnemri, E.S. (1996). In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc. Natl. Acad. U.S.A. 93, 7464-7469.
15. Fueyo, J., Gomez-Manzano, C., Yung, W.K., Liu, T.J., Alemany, R., McDonnell, T.J., Shi, X., Rao, J.S., Levin, V.A., and Kyritsis, A.P. (1998). Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nature Med. 4, 685-690.
16. Gooding, L.R., Elmore, L.W., Tollefson, A.E., Brady, H.A., and Wold, W.S. (1988). A 14, 700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 53, 341-346.
17. Gooding, L.R., Aquino, L., Duerksen-Hughes, P.J., Day, D., Horton, T.M., Yei, S.P., and Wold, W.S. (1991). The E1B 19, 000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells. J. Virol. 65, 3083-3094.
18. Graham, F.L., Smiley, J., Russell, W.C., and Nairu, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-77.
19. Hashimoto, S., Ishii, A., and Yonehara, S. (1991). The E1b oncogene of adenovirus confers cellular resistance to cytotoxicity of tumor necrosis factor and monoclonal anti-Fas antibody. Int. Immunol. 3, 343-351.
20. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. (1991). The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243.
21. Ju, S.T., Panka, D.J., Cui, H., Ettinger, R., El-Khatib, M., Sherr, D.H., Stanger, B.Z., and Marshak-Rothstein, A. (1995). Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (London) 373, 444-448.
22. Kang, S.M., Schneider, D.B., Lin, Z., Hanahan, D., Dichek, D.A., Stock, P.G., and Baekkeskov, S. (1997). Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3, 738-743.
23. Kay, M.A., Holterman, A.X., Meuse, L., Gown, A., Ochs, H.D., Linsley, P.S., and Wilson, C.B. (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nature Genet. 11, 191-197.
24. Kondo, S., Ishizaka, Y., Okada, T., Kondo, Y., Hitomi, M., Tanaka Y., Haqqi, T., Barnett, G.H., and Barna, B.P. (1998). FADD gene therapy for malignant gliomas in vitro and in vivo. Hum. Gene Ther. 9, 1599-1608.
25. Korbutt, G.S., Elliott, J.F., and Rajotte, R.V. (1997). Co-transplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 46, 317-322.
26. Larregina, A.T., Morelli, A.E., Dewey, R.A., Castro, M.G., Fontana, A., and Lowenstein, P.R. (1998). FasL induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors. Gene Ther. 5, 563-568.
27. Lau, H.T., Yu, M., Fontana, A., and Stoeckert, C.J., JR. (1996). Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112. [See comments].
28. Liu, T.J., El-Naggar, A.K., McDonnell, T.J., Steck, K.D., Wang, M., Taylor, D.L., and Clayman, G.L. (1995). Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 55(14), 3117-3122.
29. Los, M., Van De Craen, M., Penning, L.C., Schenk, H., Westendorp, M., Baeuerle, P.A., Droge, W., Krammer, P.H., Fiers, W., and Schulze-Osthoff, K. (1995). Requirements of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature (London) 375, 81-83.
30. Louis, N., Evelegh, C., and Graham, F.L. (1997). Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 233, 423-429.
31. Massie, B., Couture, F., Lamoureux, L., Mosser, D.D., Guilbault, C., Jolicoeur, P., Belanger, F., and Langelier, Y. (1998). Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J. Virol. 72, 2289-2296.
32. Muruve, D.A., Nicolson, A.G., Manfro, R.C., Strom, T.B., Sukhatme, V.P., and Libermann, T.A. (1997). Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum. Gene Ther. 8, 955-963.
33. Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E., and Dixit, V.M. (1996). FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817-827.
34. Nagata S., and Suda, T. (1995). Fas and Fas ligand: 1 pr and gld mutations. Immunol. Today 16, 39-43.
35. Okuyama, T., Li, X.K., Funeshima, N., Fujino, M., Sasaki, K., Kita, Y., Kosuga, M., Takahashi, M., Saito, H., Suzuki, S., and Yamada, M. (1998). Fas-mediated apoptosis is involved in the elimination of gene-transduced hepatocytes with E1/E3-deleted adenoviral vectors. J. Gastroenterol. Hepatol. 13(Suppl.), S113-S118.
36. Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I.A., Debatin, K.M., Fishcer, A., and De Villartay, J.P. (1995). Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347-1349.
37. Sata, M., Perlman, H., Muruve, D.A., Silver, M., Ikebe, M., Libermann, T.A., Oettgen, P., and Walsh, K. (1998). Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc. Natl. Acad. Sci. U.S.A. 95, 1213-1217.
38. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H., and Peter, M.E. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687.
39. Schowalter, D.B., Meuse, L., Wilson, C.B., Linsley, P.S., and Kay, M.A. (1997a). Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression. Gene Ther. 4, 853-860.
40. Schowalter, D.B., Tubb, J.C., Liu, M., Wilson, C.B., and Kay, M.A. (1997b). Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Gene Ther. 4, 351-360.
41. Seino, K., Kayagaki, N., Okumura, K., and Yagita, H. (1997). Antitumor effect of locally produced CD95 ligand. Nature Med. 3, 165-170.
42. Selawry, H.P., and Cameron, D.F. (1993). Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant. 2, 123-129.
43. Seth, P., Katayose, D., Li, Z., Kim, M., Wersto, R., Craig, C., Shanmugam, N., Ohri, E., Mudahar, B., Rakkar, A.N., Kodali, P., and Cowan, K. (1997). A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: A gene therapy approach for drug-resistant cancers. Cancer Gene Ther. 4, 383-390.
44. Shinoura, N., Yoshida, Y., Sadata, A., Hanada, K.I., Yamamoto, S., Kirino, T., Asai, A., and Hamada, H. (1998). Apoptosis by retrovirus-and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. Hum. Gene Ther. 9(14):1983-1993.
45. Srinivasula, S., Ahmad, M., Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. (1996). Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. U.S.A. 93, 14486-14491.
46. Swenson, K.M., Ke, B., Wang, T., Markowitz, J.S., Maggard, M.A., Spear, G.S., Imagawa, D.K., Goss, J.A., Busuttil, R.W., and Seu, P. (1998). Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 65, 155-160.
47. Takahashi, A., Hirata, H., Yonehara, S., Imai, Y., Lee, K.K., Moyer, R.W., Turner, P.C., Mesner, P.W., Okazaki, T., Sawai, H., Kishi, S., Yamamoto, K., Okuma, M., and Sasada, M. (1997). Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8. Oncogene 14, 2741-2752.
48. Tewari, M., and Dixit, V.M. (1995). Fas-and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 270, 3255-3260.
49. Vrancken Peeters, M.J., Perkins, A.L., and Kay, M.A. (1996). Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. BioTechniques 20, 278-285.
50. White, E., Sabbatini, P., Debbas, M., Wold, W.S., Kusher, D.I., and Gooding, L.R. (1942). The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha. Mol. Cell. Biol. 12, 2570-2580.
51. Zhang, H.G., Bilbao, G., Zhou, T., Contreras, J.L., Gomez-Navarro, J., Feng, M., Saito, I., Mountz, J.D., and Curiel, D.T. (1998). Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. J. Virol. 72, 2483-2490.
52. Zhou, Q., Snipas, S., Orth, K., Muzio, M., Dixit, V., and Salvesen, G. (1997). Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J. Biol. Chem. 272, 7797-7800.